학술논문

177Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
Document Type
Article
Source
Journal of Nuclear Medicine; Dec2021, Vol. 62 Issue 12, p1-27, 27p
Subject
Language
ISSN
01615505